LIPOCINE INC.

LPCN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Revenue $428.0K $0 $0 $0 $7.7M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $6.5M $11.0M $8.1M $12.6M $15.5M $5.1M $2.3M
SG&A Expense $5.3M $10.2M $10.4M $5.8M $5.0M $3.6M $1.6M $5.2K
Operating Income $-11.3M $-21.2M $-19.2M $-18.4M $-20.5M $-10.7M $3.9M
Operating Margin -2,646.0% 50.3%
Interest Expense
Pretax Income $-11.7M $-21.0M $-19.0M $-18.2M $-20.4M $-10.6M $3.9M
Income Tax Expense $700 $700 $752 $200 $200 $-55.0K $684
Net Income $-11.7M $-21.0M $-19.0M $-18.2M $-20.4M $-10.6M $3.9M $-5.2K
Net Margin -2,724.1% 50.4%
EPS (Basic) $-0.28 $-0.53 $-0.52 $-0.56 $-0.80 $-0.72 $0.43
EPS (Diluted) $-0.28 $-0.53 $-0.52 $-0.56 $-0.80 $-0.72 $0.43
Shares Outstanding (Basic) 42.7M 40.1M 36.5M 32.9M 25.5M 14.7M 8.9M 6.0M
Shares Outstanding (Diluted) 42.7M 40.1M 36.5M 32.9M 25.5M 14.7M 8.9M 6.0M
Dividends Per Share
← Newer Page 2 of 2 Older →